Articles from SK Capital Partners, LP

SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets.

SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of LISI Group’s (Euronext: FII) Medical division (the “Transaction”). The business has relocated its headquarters to Big Lake, Minnesota and has been renamed Precera Medical (“Precera Medical” or the “Company”), marking its emergence as a leading contract development and manufacturing organization (“CDMO”) partner for blue chip medical device original equipment manufacturers (“OEMs”) and innovators. As part of the Transaction, LISI Group retained a minority stake in the Company.

Affiliates of funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, together with Edgewater Capital Partners, LP (“Edgewater”), announced today they have entered into an agreement to sell Luxium Solutions (“Luxium” or the “Company”) to Excelitas Technologies Corp. (“Excelitas”), a leading provider of advanced, life-enriching technologies that make a difference, serving global market leaders in the life sciences, advanced industrial, next-generation semiconductor and avionics sectors, and a portfolio company of AEA Investors. This strategic combination will strengthen Excelitas’ technological capabilities and product portfolio, expand its market reach, and advance Luxium’s mission to deliver high-performance detection, imaging, and photonic solutions to customers worldwide. The transaction is expected to close in the next few months, subject to customary closing conditions and regulatory approvals.

SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, today announced that its affiliate has entered into exclusive negotiations with LISI Group (Euronext: FII) to acquire LISI Group’s Medical division (“Lisi Medical” or the “Company”).

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, announced today that it has completed the sale of Florachem Corporation (“Florachem” or the “Company”) to Tradebe, a global business group dedicated to sustainability. Florachem will join Tradebe’s Life Sciences business line, which is focused on creating a circular economy by purifying and manufacturing essential ingredients. This strategic combination is expected to enhance Florachem’s capabilities, expand its market reach, and further the Company’s commitment to sustainability and innovation.

Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, completed the acquisition of Physical Properties Testers Group (“PPT Group”, “PPT”, or the “Company”) from Battery Ventures (“Battery”).

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today it has completed the sale of Foremark Performance Chemicals, Inc. (“Foremark”) to affiliates of CC Industries, Inc., which is the management company for the Crown family’s privately-held companies.

SK Capital Partners, LP (“SK Capital” or the “Firm”) today announced the final closing of SK Capital Partners VI (“Fund VI”) at $2.95 billion. The fund is the latest vintage of the Firm’s Flagship private investment strategy.

Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, have completed their previously announced acquisition of J&K Ingredients, Inc. (“J&K” or the “Company”) from CORE Industrial Partners (“CORE”).

Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, have acquired Isolatek International (“Isolatek” or the “Company”). Isolatek is a market leading manufacturer and supplier of passive fireproofing technologies. The terms of the deal were not disclosed.

SK Capital Partners, LP (“SK Capital” or the “Firm”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, today announced the close of SKCP Catalyst Fund II (“Catalyst Fund II” or the “Fund”). The Fund was oversubscribed with total committed capital of $800 million, reflecting the Fund’s $750 million hard cap on Limited Partner commitments and SK Capital’s investment of an additional $50 million.

Funds advised by SK Capital Partners, LP (“SK Capital”) and Edgewater Capital Partners, LP (“Edgewater”), private investment firms focused on the specialty materials and specialty chemicals sectors, completed their previously announced acquisition of the scintillation and photonic crystals business of Saint-Gobain, S.A. The business has been renamed Luxium Solutions (“Luxium” or the “Company”), reflecting its position as an innovator and key partner for the healthcare, security, energy, and scientific research sectors.

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it has recapitalized Techmer PM, LLC (“Techmer” or the “Company”) with an investment from Gryphon Investors (“Gryphon”), a leading middle-market private equity firm. The transaction represents a successful initial phase of investment for SK Capital, which will remain a significant investor alongside Techmer founder John Manuck, and the Company’s management team. The combined knowledge and expertise of the new and continuing investors will support the future profitable growth of Techmer. The terms of the deal were not disclosed.

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it has completed the sale of NuCera Solutions (“NuCera” or the “Company”) to Chase Corporation (NYSE American: CCF), a leading manufacturer of protective materials for high reliability applications. NuCera was acquired for a purchase price of $250.0 million, pending any working capital adjustments and excluding acquisition-related costs.

Funds advised by SK Capital Partners, LP (“SK Capital”) and Edgewater Capital Partners, LP (“Edgewater”), private investment firms focused on the specialty materials and specialty chemicals sectors, today announced having entered into exclusive negotiations following submission of their binding offer to acquire the scintillation and photonic crystals business of Saint-Gobain, S.A. (“Saint-Gobain Crystals”). SK Capital will lead the investment with Edgewater acting as a meaningful minority shareholder with Board involvement.

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it has reached an agreement to sell NuCera Solutions (“NuCera” or the “Company”) to Chase Corporation (NYSE American: CCF), a leading manufacturer of protective materials for high reliability applications. NuCera was acquired for a purchase price of $250.0 million, pending any working capital adjustments and excluding acquisition-related costs.

SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, specialty chemicals, and pharmaceuticals sectors, today announced the hiring of Asim Bhatia as Director, Business Development. Mr. Bhatia will be based in New York and brings nearly 25 years of strategic corporate development, M&A, investment banking, and corporate banking experience to SK Capital. In this role, Mr. Bhatia will coordinate and lead the firm’s efforts to identify and develop new investment opportunities.

SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, specialty chemicals and pharmaceuticals sectors, today announced the hiring of Richard Jackson as Managing Director, Head of Capital Markets. Mr. Jackson will be based in New York and brings three decades of investment banking and deal making experience across Europe and the US to SK Capital. In this newly established role, Mr. Jackson will lead the firm’s efforts in obtaining committed financing for new platform investments and be responsible for managing the capital structures of the existing portfolio companies as well as the refinancing of existing debt, IPO related activities and supporting the financing of portfolio company add-on acquisitions.

Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, specialty chemicals, and pharmaceuticals sectors, today announced the acquisition of Florachem Holdings, LLC (“Florachem” or the “Company”) from an affiliate of Carmelina Capital, LLC.

SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, specialty chemicals and pharmaceuticals sectors, today announced the hiring of Anne Kolton as its first Chief Sustainability Officer. Ms. Kolton, who most recently held a similar position at the American Chemistry Council (ACC), will focus on growing SK Capital’s position as a sustainability leader in the private markets industry while identifying opportunities to enhance the performance of portfolio companies across the firm’s sectors of focus.

Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, today announced the acquisition of the Monomers, Polymers and European businesses of Deltech Holdings, LLC (“Deltech” or the “Company”).

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it reached agreement to sell Niacet Corp. (“Niacet”) to Kerry Group plc, the global taste and nutrition company, for $1,015m (€853m¹) on a cash-free, debt-free basis, subject to customary closing adjustments.

Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, today announced the purchase of the Canadian coatings company Canlak Inc., and US-based Valentus Specialty Chemicals. SK Capital plans to merge the two businesses to form a premier North American wood coatings company called Canlak Coatings (the “Company”), which will be headquartered in North Brunswick, New Jersey.